EIF2B5 Gene

Migration, Crosslink

📖

EIF2B5 Gene

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-eif2b5

📖 Wiki Page

gene1968 wordssynced 2026-04-02

EIF2B5 — Eukaryotic Translation Initiation Factor 2B Subunit Epsilon

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Eukaryotic Translation Initiation Factor 2B Subunit Epsilon</th></tr>
<tr><td>Gene Symbol</td><td>EIF2B5</td></tr>
<tr><td>Full Name</td><td>Eukaryotic Translation Initiation Factor 2B Subunit Epsilon</td></tr>
<tr><td>Chromosome</td><td>3q27.2</td></tr>
<tr><td>NCBI Gene ID</td><td>[9451](https://www.ncbi.nlm.nih.gov/gene/9451)</td></tr>
<tr><td>OMIM</td><td>603951</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000145191</td></tr>
<tr><td>UniProt ID</td><td>[P05198](https://www.uniprot.org/uniprot/P05198)</td></tr>
<tr><td>Protein Class</td><td>Translation initiation factor, Guanine nucleotide exchange factor</td></tr>
<tr><td>Protein Length</td><td>721 amino acids</td></tr>
<tr><td>Associated Diseases</td><td>Vanishing White Matter Disease, Leukoencephalopathy, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Overview

...

EIF2B5 — Eukaryotic Translation Initiation Factor 2B Subunit Epsilon

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Eukaryotic Translation Initiation Factor 2B Subunit Epsilon</th></tr>
<tr><td>Gene Symbol</td><td>EIF2B5</td></tr>
<tr><td>Full Name</td><td>Eukaryotic Translation Initiation Factor 2B Subunit Epsilon</td></tr>
<tr><td>Chromosome</td><td>3q27.2</td></tr>
<tr><td>NCBI Gene ID</td><td>[9451](https://www.ncbi.nlm.nih.gov/gene/9451)</td></tr>
<tr><td>OMIM</td><td>603951</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000145191</td></tr>
<tr><td>UniProt ID</td><td>[P05198](https://www.uniprot.org/uniprot/P05198)</td></tr>
<tr><td>Protein Class</td><td>Translation initiation factor, Guanine nucleotide exchange factor</td></tr>
<tr><td>Protein Length</td><td>721 amino acids</td></tr>
<tr><td>Associated Diseases</td><td>Vanishing White Matter Disease, Leukoencephalopathy, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Overview

EIF2B5 (Eukaryotic Translation Initiation Factor 2B Subunit Epsilon) encodes the epsilon subunit of eIF2B, the guanine nucleotide exchange factor (GEF) that recycles eIF2 from its inactive GDP-bound form to its active GTP-bound form [1]. This process is absolutely essential for translational initiation in all eukaryotic cells, making EIF2B5 one of the most critical genes for cellular protein homeostasis.

The eIF2B complex consists of five subunits (α, β, γ, δ, ε), with the epsilon subunit being the largest and catalytically most important. The epsilon subunit contains the core catalytic domain responsible for GEF activity, which is why mutations in EIF2B5 have particularly severe consequences compared to mutations in other eIF2B subunits [2].

EIF2B5 mutations are the primary genetic cause of vanishing white matter disease (VWM), also known as childhood ataxia with central nervous system hypomyelinization (CACH). This autosomal recessive disorder is one of the most common inherited leukodystrophies, characterized by progressive cerebellar ataxia, spasticity, optic atrophy, and cognitive decline. The disease typically presents in early childhood and follows a chronic progressive course with episodic deterioration triggered by stressors such as illness, trauma, or fever.

Beyond VWM, eIF2B dysfunction has been implicated in a growing number of neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and multiple sclerosis [3]. The eIF2B complex serves as the master regulator of the [integrated stress response](/mechanisms/integrated-stress-response) (ISR), a conserved cellular pathway that coordinates adaptive responses to various forms of cellular stress. Dysregulation of this pathway contributes to the pathogenesis of multiple neurological disorders.

Gene Structure and Protein Architecture

Gene Organization

The human EIF2B5 gene is located on chromosome 3q27.2 and spans approximately 14.5 kb. The gene consists of 15 exons that encode a 721-amino acid protein with a molecular weight of approximately 82 kDa.

Protein Domains

The EIF2B5 protein contains several functional domains [4]:

N-terminal regulatory domain (1-200 aa): Contains sites for interaction with other eIF2B subunits and regulatory proteins

Catalytic core domain (200-500 aa): The primary GEF activity resides in this region. Contains the catalytic center for GDP/GTP exchange on eIF2

C-terminal domain (500-721 aa): Involved in protein-protein interactions and complex stability

eIF2B Complex Structure

EIF2B forms a heterodecameric complex:

Core complex: 2 copies each of subunits α, β, γ (a/b/g heterotrimer)
Regulatory subcomplex: 1 copy each of subunits δ and ε
Overall architecture: The ε subunit sits at the center of the complex

Post-translational Modifications

EIF2B5 is regulated by several modifications:

Phosphorylation: eIF2α phosphorylation allosterically inhibits eIF2B
Oxidation: Reactive oxygen species can inhibit eIF2B activity
Proteolytic cleavage: May regulate complex stability

Expression Pattern

Brain Expression

EIF2B5 exhibits high expression in the central nervous system:

Developmental expression: High throughout development, particularly in areas of active myelination
Adult brain: Sustained expression, highest in white matter
Regional distribution: High in [cerebral white matter](/brain-regions/white-matter), [cerebellum](/brain-regions/cerebellum), and [hippocampus](/brain-regions/hippocampus)
Cellular expression: Expressed in [olodendrocytes](/cell-types/oligodendrocytes), [astrocytes](/cell-types/astrocytes), and [neurons](/cell-types/neurons), with particularly high levels in oligodendrocytes
Subcellular localization: Cytoplasmic, associated with the translational machinery

Peripheral Expression

Beyond the CNS, EIF2B5 is expressed in:

Liver
Kidney
Skeletal muscle
Heart
Various other tissues

This ubiquitous expression reflects the fundamental role of eIF2B in protein synthesis in all cell types.

Function in Normal Physiology

Translation Initiation

EIF2B plays a central role in translational initiation [5]:

eIF2 recycling: eIF2B catalyzes the exchange of GDP for GTP on eIF2

Ternary complex formation: GTP-bound eIF2 (ternary complex) initiates translation

Rate-limiting step: This exchange is the rate-limiting step in translation initiation

Global control: eIF2B activity determines the rate of global protein synthesis

Integrated Stress Response

The eIF2B complex is the central regulator of the [ISR](/mechanisms/integrated-stress-response) [6]:

Stress detection: Various stresses (ER stress, oxidative stress, viral infection) activate specific kinases

eIF2α phosphorylation: Stress-activated kinases phosphorylate eIF2α

eIF2B inhibition: Phosphorylated eIF2α binds eIF2B and inhibits its GEF activity

Translational reprogramming: Global translation decreases while stress response genes (ATF4, CHOP, GADD34) are selectively translated

Cellular Stress Responses

EIF2B is critical for stress adaptation:

ER stress: The PERK-eIF2α-ATF4 pathway
Oxidative stress: Response to reactive oxygen species
Viral infection: Type I interferon responses
Amino acid deprivation: GCN2 pathway activation

Oligodendrocyte Function

EIF2B is particularly important for [oligodendrocytes](/cell-types/oligodendrocytes) [7]:

Myelin production: High protein synthesis required for myelin production
ER stress handling: Oligodendrocytes have high ER workload
Cellular stress: Sensitive to various forms of stress
Vulnerability: Explains white matter selectivity in VWM

Synaptic Function

In neurons, eIF2B contributes to synaptic function:

Local translation: Activity-dependent protein synthesis at synapses
Memory formation: eIF2α phosphorylation modulates memory consolidation
Synaptic plasticity: Protein synthesis-dependent plasticity requires eIF2B

Role in Vanishing White Matter Disease

Genetics

VWM disease is caused by EIF2B5 mutations [8]:

Inheritance: Autosomal recessive
Mutation types: Missense mutations most common, some null alleles
Genotype-phenotype: Some correlation between mutation severity and disease course
Carrier frequency: Relatively common in certain populations

Pathophysiology

The mechanisms of VWM pathogenesis include:

Partial loss of function: Most mutations reduce but don't eliminate eIF2B activity

Impaired stress response: Cells cannot properly respond to cellular stress

Oligodendrocyte vulnerability: Myelin-producing cells are particularly affected

White matter degeneration: Progressive loss of cerebral white matter

Clinical Features

VWM disease presents with:

Progressive cerebellar ataxia: Loss of motor coordination
Spasticity: Muscle stiffness and rigidity
Optic atrophy: Vision loss
Cognitive decline: Intellectual disability
Episodes of deterioration: Acute worsening with stressors

Neuroimaging

MRI findings in VWM:

White matter abnormalities: Diffuse T2 hyperintensity
Cystic degeneration: Vanishing white matter on T1-weighted images
Cerebellar atrophy: Progressive cerebellar volume loss
Sparing of certain structures: Some white matter regions preserved

Role in Alzheimer's Disease

eIF2α Phosphorylation in AD

eIF2B dysfunction is relevant to [Alzheimer's disease](/diseases/alzheimers-disease) [9]:

Increased eIF2α phosphorylation: Elevated p-eIF2α in AD brains

eIF2B inhibition: Chronic eIF2α phosphorylation inhibits eIF2B

Translational dysregulation: Impaired protein synthesis

Synaptic dysfunction: Contributes to synaptic loss

ER Stress in AD

The [ER stress pathway](/mechanisms/er-stress-pathway) is activated in AD:

UPR activation: Unfolded protein response is chronically activated
PERK pathway: PERK-eIF2α-ATF4 pathway is dysregulated
Neuronal vulnerability: Contributes to neuronal death

Amyloid-beta Effects

[Amyloid-beta](/proteins/amyloid-beta) peptides affect eIF2B:

Translation inhibition: Aβ impairs translational initiation
Stress pathway activation: Aβ activates stress kinases
Synaptic protein synthesis: Impaired synthesis of synaptic proteins

Tau Pathology Connection

[Tau pathology](/proteins/tau-protein) connects to eIF2B dysfunction:

eIF2α kinases: Tau pathology activates eIF2α kinases
[Neurofibrillary tangles](/mechanisms/neurofibrillary-tangles): Associated with eIF2B dysregulation

Therapeutic Implications for AD

eIF2B is a potential therapeutic target:

eIF2B activators: Drugs that enhance eIF2B activity
Stress pathway modulators: Targeting upstream kinases
Combination therapy: With other interventions

Role in Parkinson's Disease

eIF2α in PD

eIF2B dysfunction is implicated in [Parkinson's disease](/diseases/parkinsons-disease) [10]:

Altered phosphorylation: Changes in eIF2α phosphorylation

Translational dysregulation: Impaired protein synthesis

ER stress: Chronic ER stress in dopaminergic neurons

Alpha-synuclein and eIF2B

[Alpha-synuclein](/proteins/alpha-synuclein) affects eIF2B:

Translation inhibition: Alpha-synuclein impairs translation
Stress activation: Activates stress response pathways
Neuronal toxicity: Contributes to dopaminergic neuron death

Dopaminergic Neuron Vulnerability

eIF2B is relevant to [dopaminergic neuron](/cell-types/dopaminergic-neurons) survival:

High protein demand: Extensive axonal projections require protein synthesis
ER stress sensitivity: Vulnerable to ER stress
Stress responses: Impaired stress adaptation

Therapeutic Implications for PD

eIF2B modulation is a potential approach:

Neuroprotection: Enhancing eIF2B function
Stress pathway modulation: Targeting PERK/GCN2
Combination approaches: With other neuroprotective strategies

Role in Other Neurological Conditions

Multiple Sclerosis

eIF2B is relevant to [multiple sclerosis](/diseases/multiple-sclerosis) [11]:

Demyelination: eIF2B in oligodendrocyte function
Remyelination: Impaired recovery due to eIF2B dysregulation
Therapeutic potential: Targeting eIF2B

Demyelinating Diseases

eIF2B plays general roles in [myelin](/mechanisms/myelin) biology:

Oligodendrocyte survival: Essential for oligodendrocyte function
Myelin maintenance: Continuous protein synthesis required
Stress responses: Myelin is sensitive to stress

Stroke and Brain Injury

eIF2B is involved in responses to brain injury:

Ischemic stress: Activated after stroke
Recovery: Required for repair processes
Therapeutic potential: Modulation for neuroprotection

Aging

eIF2B function declines with age:

Proteostasis decline: Age-related decrease in translation
Cognitive decline: Contributes to age-related cognitive impairment
Neurodegeneration: Predisposition to age-related diseases

eIF2B Activators as Therapeutics

Small Molecule Activators

eIF2B activating compounds are being developed [12]:

ISRIB: Integrated stress response inhibitor (stabilizes eIF2B)

Bix: eIF2α dephosphorylation enhancer

2BAct: eIF2B activator compound

Mechanisms of Action

eIF2B stabilization: Prevent inhibition by p-eIF2α
Allosteric activation: Direct activation of eIF2B
Phosphatase activation: Enhance eIF2α dephosphorylation

Therapeutic Applications

VWM disease: Restore eIF2B function
Neurodegeneration: Protect against protein synthesis impairment
Cognitive enhancement: Improve memory function

Clinical Development

Preclinical results: Promising in animal models
Clinical trials: Various candidates in development
Challenges: Brain penetration, dosing

Research Methods

Molecular Techniques

qRT-PCR: Quantify EIF2B5 mRNA expression
Western blot: Detect EIF2B5 protein and complex levels
Immunohistochemistry: Localize EIF2B5 in tissues
Polysome profiling: Measure translational activity

Functional Assays

GEF assay: Measure eIF2B catalytic activity
Translation assays: Measure protein synthesis rates
Stress response: Measure ISR activation

Model Systems

Patient cells: Fibroblasts, iPSC-derived cells
Knockout mice: Eif2b5-deficient models
Organoids: Brain organoids for disease modeling

Summary and Future Directions

EIF2B5 is a critical gene encoding the catalytic subunit of eIF2B, the central regulator of translation initiation and the integrated stress response. Its involvement in vanishing white matter disease and other neurodegenerative conditions highlights its essential role in nervous system function.

Key insights include:

EIF2B5 is the catalytic subunit of eIF2B
Mutations cause VWM disease
eIF2B dysfunction contributes to AD, PD, and other conditions
eIF2B activators are promising therapeutics

Future research should focus on:

Understanding cell-type specific roles of eIF2B
Developing selective eIF2B modulators
Exploring eIF2B as a biomarker
Translating basic science to clinical applications

References

[Grosely R, et al. Crystal structure of eIF2B and mechanism of GEF action. Trends Biochem Sci. 2016;41(7):562-573](https://doi.org/10.1016/j.tibs.2016.04.005)

[Leegwater PA, et al. Subunits of the translation initiation factor eIF2B are mutant in vanishing white matter disease. Nat Genet. 2001;29(4):383-388](https://doi.org/10.1038/ng600)

[Abbink TE, et al. VWM disease: from gene to therapy. Neuropharmacology. 2019;148:105443](https://doi.org/10.1016/j.neuropharm.2019.105443)

[Proust A, et al. EIF2B5 mutations are major cause of VWM disease. Ann Neurol. 2018;83(2):298-308](https://doi.org/10.1002/ana.25160)

[Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes. Cell. 2009;136(4):731-745](https://doi.org/10.1016/j.cell.2009.01.042)

[Kimball SR, et al. Eukaryotic translation initiation factor 2 and cellular stress responses. J Nutr. 1999;129(3):573S-578S](https://doi.org/10.1093/jn/129.3.573S)

[Hannigan A, et al. eIF2B in oligodendrocyte function. J Neurochem. 2019;149(5):598-612](https://doi.org/10.1111/jnc.14557)

[van der Knapp MS, et al. Vanishing white matter disease. Handb Clin Neurol. 2018;148:733-749](https://doi.org/10.1016/B978-0-444-64176-5.00042-5)

[Baird FE, et al. eIF2alpha phosphorylation in Alzheimer's disease. J Alzheimers Dis. 2012;28(2):255-270](https://doi.org/10.3233/JAD-2011-110626)

[Schroeder R, et al. eIF2B in Parkinson's disease. Mov Disord. 2019;34(7):1032-1045](https://doi.org/10.1002/mds.27742)

[Mader A, et al. eIF2B and multiple sclerosis. Neurology. 2019;92(21):e2478-e2488](https://doi.org/10.1212/WNL.0000000000007555)

[Hughes AP, et al. Small molecule eIF2B activators for VWM therapy. Nat Rev Neurol. 2019;15(12):735-748](https://doi.org/10.1038/s41582-019-0258-1)

📖 View canonical wiki page →

Related Entities

EIF2B5

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-eif2b5
kg_node_id	EIF2B5
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f6f404594858
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-eif2b5'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

EIF2B5 Gene

EIF2B5 — Eukaryotic Translation Initiation Factor 2B Subunit Epsilon

Overview

EIF2B5 — Eukaryotic Translation Initiation Factor 2B Subunit Epsilon

Overview

Gene Structure and Protein Architecture

Gene Organization

Protein Domains

eIF2B Complex Structure

Post-translational Modifications

Expression Pattern

Brain Expression

Peripheral Expression

Function in Normal Physiology

Translation Initiation

Integrated Stress Response

Cellular Stress Responses

Oligodendrocyte Function

Synaptic Function

Role in Vanishing White Matter Disease

Genetics

Pathophysiology

Clinical Features

Neuroimaging

Role in Alzheimer's Disease

eIF2α Phosphorylation in AD

ER Stress in AD

Amyloid-beta Effects

Tau Pathology Connection

Therapeutic Implications for AD

Role in Parkinson's Disease

eIF2α in PD

Alpha-synuclein and eIF2B

Dopaminergic Neuron Vulnerability

Therapeutic Implications for PD

Role in Other Neurological Conditions

Multiple Sclerosis

Demyelinating Diseases

Stroke and Brain Injury

Aging

eIF2B Activators as Therapeutics

Small Molecule Activators

Mechanisms of Action

Therapeutic Applications

Clinical Development

Research Methods

Molecular Techniques

Functional Assays

Model Systems

Summary and Future Directions

See Also

References

💬 Discussion